Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
302 trials
Recruiting nowPhase 1
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Recruiting nowPhase 2
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Recruiting nowPhase 2
Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer
Recruiting nowPhase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Recruiting nowPhase 2
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
Recruiting nowPhase 2
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment
Recruiting nowPhase 2
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
Recruiting nowPhase 2
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Recruiting nowPhase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Recruiting nowPhase 1
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Recruiting nowPhase 1
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
Recruiting nowPhase 2
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Recruiting nowPhase 2
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Recruiting nowPhase 2
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
Recruiting nowPhase 2
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors